touchREV Endocrinol. 2024 Apr;20(1):5-9. doi: 10.17925/EE.2023.20.1.1. Epub 2023 Nov 8.

ABSTRACT

There has been an exponential increase in the global prevalence of fatty liver disease in recent years in association with the obesity pandemic worldwide. ‘Metabolic dysfunction-associated fatty liver disease’, the new terminology adopted by an international panel of experts in 2020 to largely replace the old term ‘non-alcoholic fatty liver disease’, has now been accepted by most hepatologists and diabetologists across the globe. The term metabolic dysfunction-associated fatty liver disease was created to better reflect the metabolicand liver-specific manifestations and complications of fatty liver disease. It is important to disseminate our current understanding of this enigmatic disease among the global scientific fraternity. Recent publications, including articles from the latest issue of Endocrinology & Metabolism Clinics of North America, are attempting to fill this knowledge gap.

PMID:38812662 | PMC:PMC11132654 | DOI:10.17925/EE.2023.20.1.1